OneMedNet Corporation (ONMD)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OneMedNet Corporation (ONMD) trades at $0.80 with AI Score 45/100 (Weak). OneMedNet Corporation provides clinical imaging solutions through its iRWD platform, utilizing AI to de-identify, search, and curate imaging data. Market cap: 27M, Sector: Healthcare.
Last analyzed: Feb 8, 2026OneMedNet Corporation (ONMD) Healthcare & Pipeline Overview
OneMedNet Corporation pioneers AI-driven clinical imaging solutions, offering iRWD to securely de-identify and curate data for medical research, positioning itself as a key enabler for advancements in life sciences and diagnostics with a market cap of $0.02 billion.
Investment Thesis
OneMedNet Corporation presents a speculative investment opportunity within the healthcare information services sector. The company's iRWD platform, leveraging AI for clinical imaging data curation, addresses a growing need for secure and efficient data sharing in medical research. While the company's negative profit margin of -411.1% and gross margin of -151.3% raise concerns, the potential for growth lies in expanding its partner network and increasing adoption of its iRWD platform. The company's beta of 1.14 suggests higher volatility compared to the market. Successful execution of its growth strategies and achieving profitability are critical for realizing value. Investors should carefully consider the risks associated with the company's financial performance and market position before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.02 billion reflects its small size and growth potential in the clinical imaging solutions market.
- P/E Ratio of -13.22 indicates the company is currently not profitable, suggesting a high-risk, high-reward investment.
- Negative Profit Margin of -411.1% highlights significant challenges in achieving profitability and operational efficiency.
- Gross Margin of -151.3% indicates the company's cost of revenue exceeds its revenue, requiring strategic adjustments.
- Beta of 1.14 suggests the stock is more volatile than the market, potentially offering higher returns but also greater risk.
Competitors & Peers
Strengths
- Proprietary iRWD platform with AI capabilities
- Focus on secure data de-identification and curation
- Partnerships with medical and academic institutions
- Potential for scalability through cloud-based deployment
Weaknesses
- Negative profit and gross margins
- Limited market presence and brand recognition
- Reliance on a single product (iRWD)
- Small number of employees
Catalysts
- Ongoing: Expansion of the iRWD platform to new medical research institutions.
- Upcoming: Development and launch of new AI-powered features for iRWD in Q3 2026.
- Ongoing: Strategic partnerships with pharmaceutical companies for drug discovery applications.
- Upcoming: Transition of iRWD to a cloud-based platform by Q4 2026.
Risks
- Ongoing: Negative profit and gross margins pose a significant threat to financial sustainability.
- Potential: Intense competition from larger, more established healthcare IT providers could limit market share.
- Potential: Evolving data privacy regulations may require costly compliance measures.
- Potential: Cybersecurity risks associated with data sharing could damage reputation and lead to financial losses.
- Ongoing: Reliance on a single product (iRWD) makes the company vulnerable to market shifts and technological advancements.
Growth Opportunities
- Expanding the iRWD Platform to New Geographies: OneMedNet can pursue geographic expansion by targeting medical research institutions and healthcare providers in new regions. The global market for healthcare IT solutions is projected to reach $390.7 billion by 2028, presenting a significant opportunity for OneMedNet to increase its market share. This expansion could be achieved through strategic partnerships, direct sales efforts, and participation in industry conferences. Timeline: 2-3 years.
- Developing New AI-Powered Features for iRWD: OneMedNet can enhance its iRWD platform by incorporating new AI-powered features, such as advanced image analysis, predictive analytics, and personalized medicine applications. The AI in healthcare market is expected to reach $95.7 billion by 2030, driven by the increasing demand for AI-based solutions in diagnostics, treatment planning, and drug discovery. This would require investment in research and development and collaboration with AI experts. Timeline: 1-2 years.
- Strategic Partnerships with Pharmaceutical Companies: OneMedNet can forge strategic partnerships with pharmaceutical companies to leverage its iRWD platform for drug discovery and clinical trials. The pharmaceutical industry is increasingly relying on real-world data and AI to accelerate drug development and improve clinical trial outcomes. By providing secure and curated imaging data, OneMedNet can help pharmaceutical companies identify potential drug targets, optimize clinical trial designs, and monitor treatment response. Timeline: 1-2 years.
- Offering iRWD as a Cloud-Based Solution: Transitioning iRWD to a cloud-based platform can enhance its scalability, accessibility, and cost-effectiveness. The cloud computing in healthcare market is projected to reach $76.9 billion by 2027, driven by the increasing adoption of cloud-based solutions for data storage, analytics, and application deployment. This would involve migrating the iRWD platform to a cloud infrastructure and offering it as a software-as-a-service (SaaS) solution. Timeline: 1 year.
- Targeting Smaller Research Institutions and Clinics: OneMedNet can expand its customer base by targeting smaller research institutions and clinics that may not have the resources to develop their own data curation solutions. This would involve tailoring the iRWD platform to meet the specific needs of smaller organizations and offering flexible pricing models. The market for healthcare IT solutions among smaller providers is growing, driven by the increasing adoption of electronic health records and the need for data-driven decision-making. Timeline: Ongoing.
Opportunities
- Expanding into new geographic markets
- Developing new AI-powered features for iRWD
- Forging strategic partnerships with pharmaceutical companies
- Targeting smaller research institutions and clinics
Threats
- Intense competition from established healthcare IT providers
- Evolving data privacy regulations
- Potential for technological obsolescence
- Cybersecurity risks associated with data sharing
Competitive Advantages
- Proprietary AI-powered iRWD platform
- Established network of medical and academic research partners
- Expertise in secure data de-identification and curation
- First-mover advantage in the niche of AI-driven clinical imaging data solutions
About ONMD
OneMedNet Corporation, headquartered in Eden Prairie, Minnesota, is a healthcare information services company focused on providing clinical imaging solutions. The company's core offering is iRWD, a platform that leverages artificial intelligence to securely de-identify, search, and curate imaging data. This technology is designed to facilitate medical and academic research by providing a streamlined and secure method for accessing and utilizing clinical imaging data. OneMedNet partners with a network of medical and academic research institutions, enabling them to accelerate progress in medical research, discovery, and diagnostics across various life science fields. The iRWD platform addresses the critical need for secure and efficient data sharing in the healthcare industry, helping to bridge the gap between data accessibility and patient privacy. With a focus on innovation and collaboration, OneMedNet aims to drive advancements in medical research and improve patient outcomes through its cutting-edge imaging solutions.
What They Do
- Provides clinical imaging solutions to healthcare providers and research institutions.
- Offers iRWD, an AI-powered platform for de-identifying, searching, and curating imaging data.
- Facilitates secure data sharing for medical research and discovery.
- Enables advancements in diagnostics and treatment planning.
- Partners with medical and academic institutions to accelerate research.
- Utilizes AI to improve the efficiency and accuracy of data analysis.
- Supports the development of personalized medicine approaches.
Business Model
- Offers iRWD platform as a service to medical and academic research institutions.
- Generates revenue through subscription fees or licensing agreements.
- Potentially charges for data curation and analysis services.
- May explore partnerships with pharmaceutical companies for drug discovery applications.
Industry Context
OneMedNet Corporation operates within the healthcare information services industry, a sector experiencing rapid growth driven by the increasing adoption of digital health technologies and the need for efficient data management. The market is characterized by intense competition, with companies vying to provide innovative solutions for data sharing, analysis, and security. OneMedNet's iRWD platform positions it within the niche of AI-driven clinical imaging data curation, catering to the specific needs of medical and academic research institutions. The company competes with other players in the healthcare IT space, including those focused on data analytics, cloud-based solutions, and medical imaging software. The increasing demand for personalized medicine and the growing volume of healthcare data are key trends shaping the industry landscape.
Key Customers
- Medical research institutions
- Academic research institutions
- Hospitals and clinics
- Pharmaceutical companies (potential)
Financials
Chart & Info
OneMedNet Corporation (ONMD) stock price: $0.80 (+0.04, +5.67%)
Latest News
-
OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights
GlobeNewswire · Mar 18, 2026
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Mar 3, 2026
-
12 Health Care Stocks Moving In Friday's Intraday Session
benzinga · Feb 27, 2026
-
Dow Dips Over 600 Points; US Producer Prices Increase In January
benzinga · Feb 27, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ONMD.
Price Targets
Wall Street price target analysis for ONMD.
MoonshotScore
What does this score mean?
The MoonshotScore rates ONMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Friday's Intraday Session
Dow Dips Over 600 Points; US Producer Prices Increase In January
ONMD Healthcare Stock FAQ
What does OneMedNet Corporation do?
OneMedNet Corporation specializes in providing clinical imaging solutions through its iRWD platform. This platform utilizes artificial intelligence to securely de-identify, search, and curate imaging data, catering primarily to medical and academic research institutions. By facilitating secure and efficient data sharing, OneMedNet enables advancements in medical research, discovery, and diagnostics. The company's focus on AI-driven data curation positions it as a key enabler for personalized medicine and improved patient outcomes, addressing the growing need for secure and accessible healthcare data.
Is ONMD stock worth researching?
ONMD stock presents a high-risk, high-reward investment opportunity. While the company's negative profit margin of -411.1% and gross margin of -151.3% raise concerns, the potential for growth in the healthcare information services sector is significant. The company's iRWD platform offers a unique solution for secure data sharing, but its success depends on expanding its customer base and achieving profitability. Investors should carefully weigh the risks and potential rewards before considering ONMD stock, considering its volatile nature indicated by a beta of 1.14.
What are the main risks for ONMD?
OneMedNet faces several key risks, including its current financial performance with negative profit and gross margins, indicating a struggle for profitability. Intense competition from larger, more established healthcare IT providers poses a threat to market share. Evolving data privacy regulations could require significant investments in compliance. Cybersecurity risks associated with data sharing could lead to reputational damage and financial losses. The company's reliance on a single product, iRWD, makes it vulnerable to market shifts and technological obsolescence, requiring continuous innovation and diversification.
What are the key factors to evaluate for ONMD?
OneMedNet Corporation (ONMD) currently holds an AI score of 45/100, indicating low score. Key strength: Proprietary iRWD platform with AI capabilities. Primary risk to monitor: Ongoing: Negative profit and gross margins pose a significant threat to financial sustainability.. This is not financial advice.
How frequently does ONMD data refresh on this page?
ONMD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ONMD's recent stock price performance?
Recent price movement in OneMedNet Corporation (ONMD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary iRWD platform with AI capabilities. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ONMD overvalued or undervalued right now?
Determining whether OneMedNet Corporation (ONMD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ONMD?
Before investing in OneMedNet Corporation (ONMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available. The company's future performance is highly dependent on the successful adoption of its iRWD platform and its ability to achieve profitability.